Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial f…
Biotechnology
US, Redwood City [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 41.23 | 18.45 | 13.06 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -58.57 | 1.42 | 3.43 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | -19.02 | 10.47 | 12.93 | |
| Cash | -21.20 | 10.34 | 13.12 | |
| Capex | -17.15 | -0.02 | -0.02 | |
| Free Cash Flow | -14.20 | -0.99 | -0.87 | |
| Revenue | inf | 0.00 | < 0.005 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | inf | 0.00 | -2.85 | |
| Operating Margin | inf | 0.00 | -242.56 | |
| ROA | 21.41 | -0.06 | -0.08 | |
| ROE | 24.00 | -0.07 | -0.09 | |
| ROIC | 19.53 | -0.08 | -0.09 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of RVMD is permitted for members.
5
Growth
The "Growth Entry" for the Focus of RVMD is permitted for members.
6
Leverage & Liquidity